A new study from High Rise Financial examining U.S. prescription drug safety warns that the medications millions of Americans depend on each day can also become a serious source of preventable harm, especially when recalls, quality failures, and medication complexity collide. According to the Health Policy Institute, more than 131 million people in the U.S. (about 66% of adults) rely on prescription drugs. Yet CDC-backed national data shows that medication-related problems, ranging from polypharmacy and dosing errors to product quality failures, are tied to an estimated 1.5 million emergency department visits each year, and roughly one-third of hospital visits due to adverse drug effects lead to admission, underscoring the severity of medication-related injuries.
The study goes beyond basic national statistics to highlight what’s actually being reported in recall notices and adverse drug event (ADE) trends: which drugs are being recalled most frequently, why recalls occur, what types of injuries are common, and which age groups face the highest risk. It also offers a clear consumer message: many dangerous medication events are preventable, but only if patients, providers, and systems catch the warning signs early, and if patients know how to verify whether a recalled product is sitting in their own home.
Notable Prescription Drug Recalls in 2025
In 2025, FDA recall data revealed that prescription drug recalls impacted a wide range of commonly used medications, including those used to manage blood pressure, cholesterol, chronic pain, neurological conditions, thyroid disorders, and diabetes. The scale and diversity of recalled products reinforce that drug safety concerns are not limited to “rare” medications or fringe categories; some of the most widely used treatments in America appeared in recall reports.
One of the largest publicly disclosed recalls in 2025 involved prazosin hydrochloride, a medication used for high blood pressure and sometimes prescribed for PTSD-related symptoms. Approximately 580,844 bottles were recalled after testing identified nitrosamine impurities above acceptable safety limits—a category of contaminants that has raised major health concerns in recent years due to potential links to increased cancer risk when exposure is elevated or prolonged.
Another major recall affected atorvastatin calcium, one of the most commonly prescribed statins in the United States. Nearly 142,000 bottles were recalled due to failed dissolution testing, raising concerns that the medication might not break down properly in the body and could deliver inconsistent therapeutic effects. When a drug does not dissolve as intended, patients may receive less benefit than expected—creating risks of undertreated cardiovascular disease and other complications.
The 2025 recall landscape also included manufacturing cross-contamination risks. Ziac, a combination blood pressure medication containing bisoprolol and hydrochlorothiazide, was recalled (more than 11,000 bottles) after cross-contamination with a cholesterol-lowering drug was identified during manufacturing. Cross-contamination is especially concerning because it can expose patients to unintended medications—raising the likelihood of side effects, contraindications, or dangerous interactions.
Beyond high-unit recalls with publicly disclosed bottle counts, the study noted that many widely used generics were subject to lot-based recalls, where the FDA identifies affected lot numbers rather than broad unit totals. Medications named in 2025 recall activity included widely used treatments such as gabapentin and lacosamide (seizures and nerve pain), levothyroxine (thyroid hormone replacement), and metformin extended-release (type 2 diabetes), alongside targeted lot recalls affecting pravastatin sodium, cyclobenzaprine hydrochloride, and indomethacin extended-release.
Why Recalls Matter for Patient Harm
Recalls exist to protect patients, but they do not always remove risk instantly. If a defect goes undetected, if communication is delayed, or if the recall affects only certain lots, unsafe medication can remain in circulation temporarily, sometimes long enough to contribute directly to ADEs. Manufacturing failures like contamination, incorrect strength, improper dissolution, or labeling errors can lead to therapeutic failure, toxic exposure, or dangerous drug interactions, especially in patients already juggling multiple prescriptions.
“Check Your Medicine Cabinet” Guidance
Because recalls often target specific lots, the study emphasizes that consumers should not assume a recall means “every bottle everywhere” is affected, or that a medication is safe simply because it’s a familiar name. Patients can take straightforward steps to reduce risk:
- Check the prescription label for the drug name, dosage, manufacturer, lot number, and expiration date.
- Ask a pharmacist to verify whether the medication is tied to a recall notice or enforcement report.
- Monitor recall alerts and keep a written list of current medications, including dose and prescriber, especially for households managing chronic conditions.
The Bottom Line
America’s medication system saves lives, but it also generates a heavy burden of preventable harm. With tens of millions of adults relying on prescriptions, and with recall activity spanning everything from heart and cholesterol drugs to diabetes and thyroid medications, the study concludes that medication safety needs to be treated as a daily public health issue, not a rare crisis. Recalls, quality failures, and complex regimens can intersect quickly, making vigilance at the pharmacy counter and at home an essential part of staying safe.